Al Khleifat, Ahmad http://orcid.org/0000-0002-7406-9831
Iacoangeli, Alfredo
van Vugt, Joke J. F. A.
Bowles, Harry
Moisse, Matthieu http://orcid.org/0000-0001-8880-9311
Zwamborn, Ramona A. J.
van der Spek, Rick A. A. http://orcid.org/0000-0001-9983-204X
Shatunov, Aleksey
Cooper-Knock, Johnathan
Topp, Simon
Byrne, Ross http://orcid.org/0000-0002-4082-6072
Gellera, Cinzia
López, Victoria http://orcid.org/0000-0001-8129-8352
Jones, Ashley R. http://orcid.org/0000-0003-0470-0058
Opie-Martin, Sarah
Vural, Atay
Campos, Yolanda
van Rheenen, Wouter http://orcid.org/0000-0002-5860-1533
Kenna, Brendan http://orcid.org/0000-0001-7591-2221
Van Eijk, Kristel R.
Kenna, Kevin
Weber, Markus
Smith, Bradley
Fogh, Isabella
Silani, Vincenzo
Morrison, Karen E. http://orcid.org/0000-0003-0216-5717
Dobson, Richard http://orcid.org/0000-0003-4224-9245
van Es, Michael A. http://orcid.org/0000-0002-7709-5883
McLaughlin, Russell L. http://orcid.org/0000-0003-3915-2135
Vourc’h, Patrick
Chio, Adriano http://orcid.org/0000-0001-9579-5341
Corcia, Philippe
de Carvalho, Mamede http://orcid.org/0000-0001-7556-0158
Gotkine, Marc http://orcid.org/0000-0003-2541-6232
Panades, Monica P.
Mora, Jesus S. http://orcid.org/0000-0001-6633-5354
Shaw, Pamela J.
Landers, John E. http://orcid.org/0000-0001-8084-5043
Glass, Jonathan D. http://orcid.org/0000-0002-3295-4971
Shaw, Christopher E.
Basak, Nazli
Hardiman, Orla
Robberecht, Wim
Van Damme, Philip http://orcid.org/0000-0002-4010-2357
van den Berg, Leonard H.
Veldink, Jan H. http://orcid.org/0000-0001-5572-9657
Al-Chalabi, Ammar http://orcid.org/0000-0002-4924-7712
Funding for this research was provided by:
Motor Neurone Disease Association
RCUK | MRC | Medical Research Foundation
Wellcome Trust
Article History
Received: 15 December 2020
Accepted: 21 October 2021
First Online: 28 January 2022
Competing interests
: A.A.C. is a consultant for Mitsubishi-Tanabe Pharma, GSK, and Chronos Therapeutics, and chief investigator for clinical trials for Cytokinetics and OrionPharma. J.H.V. is a consultant for Biogen. L.H.V.D.B. reports grants from Netherlands ALS Foundation, grants from The Netherlands Organization for Health Research and Development (Vici scheme), grants from The European Community’s Health Seventh Framework Programme (grant agreement no. 259867 (EuroMOTOR)), grants from The Netherlands Organization for Health Research and Development)the STRENGTH project, funded through the EU Joint Programme – Neurodegenerative Disease Research, JPND), during the conduct of the study; personal fees from Calico, personal fees from Cytokinetics, grants and personal fees from Takeda, non-financial support from Orion, non-financial support from Orphazyme, outside the submitted work. CES reports grants from Avexis, grants from Eli Lilly, grants from Chronos Therapeutics, grants from Vertex Pharmaceuticals, during the conduct of the study; grants from QurAlis, grants from Chronos Therapeutics, grants from Biogen, outside the submitted work. A.A.K., O.H., M.P.P., J.S.M., P.J.S., J.E.L., C.E.S., N.B., O.H., W.R., P.V.D., N.B., K.K., B.K., H.B., and L.H.V.B. declare no competing interests.